Regeneron sees EYLEA HD momentum but warns biosimilar competition

Regeneron says EYLEA HD is gaining market momentum, but notes looming biosimilar competition could limit future growth. The company also says cemdisiran is positioned for launch in myasthenia gravis to support its immunology pipeline.